HCW Biologics Inc. Received NASDAQ Staff Determination Letter
December 23, 2024 08:10 ET
|
HCW Biologics, Inc
Mandatory press release to disclose receipt of Nasdaq Staff Determination Letter.
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
November 18, 2024 21:27 ET
|
HCW Biologics, Inc
HCW Biologics Announces Pricing of $6.9 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under NASDAQ Rules
HCW Biologics and WY Biotech Announce License Agreement for Immunotherapeutic Product Candidate
November 18, 2024 07:00 ET
|
HCW Biologics, Inc
HCW Biologics signed license agreement with WY Biotech
HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights
November 14, 2024 16:40 ET
|
HCW Biologics, Inc
Press release for Q3 2024 business highlights and financial results
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights - Correction
August 23, 2024 16:30 ET
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights
August 14, 2024 16:35 ET
|
HCW Biologics, Inc
Results of Q2 2024, including settlement of long-running arbitration.
HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights
May 15, 2024 16:39 ET
|
HCW Biologics, Inc
Earning release for Q1 2024
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights
April 01, 2024 16:10 ET
|
HCW Biologics, Inc
Q4 and Year End Earnings Release and Business Highlights
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
November 14, 2023 07:00 ET
|
HCW Biologics, Inc
HCW Biologics Reports Third Quarter 2023 Financial Results And Recent Business Highlights
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
November 08, 2023 07:30 ET
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.